Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10704384 | 0.80 | TSHR (0.42) | CA14CA12L3MBTL1TSHRCA1 | |
| SCHEMBL10012464 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14KMT2ACA12MEN1 | |
| SCHEMBL31468683 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14KMT2ACA12MEN1 | |
| SCHEMBL13741138 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14KMT2ACA12ALDH1A1 | |
| SCHEMBL13741176 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14KMT2ACA12ALDH1A1 | |
| SCHEMBL4446595 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14KMT2ACA12ALDH1A1 | |
| SCHEMBL5864497 | 0.77 | TSHR (0.50) | SMN1; SMN2CA14KMT2ACA12MAPT | |
| SCHEMBL6882473 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14KMT2ACA12ALDH1A1 | |
| SCHEMBL10017663 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14KMT2ACA12ALDH1A1 | |
| SCHEMBL866170 | 0.77 | TSHR (0.50) | SMN1; SMN2CA14KMT2ACA12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0163435-B1 | PREPARATION OF 2-CHLOROPROPIONIC ACID ESTERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-10-26 | — | — | EP | claimed |
| EP-0163435-A2 | Preparation of 2-chloropropionic acid esters | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-04 | — | — | EP | claimed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| EP-2800565-B1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-2029516-B1 | PROCESS FOR PREPARING FLUORINATED MOLECULES | BAYER IP GMBH (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2029516-A1 | PROCESS FOR PREPARING FLUORINATED MOLECULES | Bayer CropScience AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-20070287855-A1 | Process for Preparing Fluorinated Molecules | BAYER CROPSCIENCE AG (DE) | 2007-12-13 | — | — | US | disclosed |
| WO-2007140908-A1 | PROCESS FOR PREPARING FLUORINATED MOLECULES | BAYER CROPSCIENCE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| US-20050014787-A1 | 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1443041-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-0163435-B1 | PREPARATION OF 2-CHLOROPROPIONIC ACID ESTERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-10-26 | — | — | EP | disclosed |
| EP-0163435-A2 | Preparation of 2-chloropropionic acid esters | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287855-A1 | Process for Preparing Fluorinated Molecules | HDHD5, CYP8B1, DHCR7 | SMN1; SMN2 4742/4885CA14 1023/4885KMT2A 2185/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | SMN1; SMN2 2374/4885CA14 1310/4885KMT2A 1102/4885 |
| US-20050014787-A1 | 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof | F2, HYPK, F10 | SMN1; SMN2 1472/4885CA14 1198/4885KMT2A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.